FLT4 抗体
Quick Overview for FLT4 抗体 (ABIN1589703)
抗原
See all FLT4 抗体适用
宿主
克隆类型
标记
应用范围
克隆位点
-
-
原理
- VEGFR-3/FLT-4 antibody
-
特异性
- Recombinant human soluble VEGFR-3/FLT-4
-
交叉反应 (详细)
- The antibody will detect native human VEGFR-1/Flt-1 in ELISA experiments, WB, IF and IP.
-
产品特性
-
Chromosomal location: 5q35.3
This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified recombinant human Vascular Endothelial Growth Factor Receptor 3 (recombinant human VEGFR-3/FLT-4) extracellular domain. -
纯化方法
- Protein-G affinity chromatography
-
免疫原
- Recombinant human soluble VEGFR-3/FLT-4
-
亚型
- IgG1
-
-
-
-
应用备注
- ELISA: Use at 1-5 μg/mL, Western Blot: Use at 1-5 μg/mL, IF/ IHC: Use at 1-10 μg/mL.
-
限制
- 仅限研究用
-
-
-
状态
- Lyophilized
-
溶解方式
- Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/mL.
-
缓冲液
- PBS
-
注意事项
- Centrifuge vial prior to opening.
-
储存条件
- 4 °C,-20 °C
-
储存方法
- The lyophilized antibody is stable for at least 2 years at -20°C. After sterile reconstitution the antibody is stable at 2-8°C for up to 6 months. Frozen aliquots are stable for at least 6 months when stored at -20°C. Addition of a carrier protein or 50% glycerol is recommended for frozen aliquots.
-
有效期
- 24 months
-
-
-
Molecular and cellular effects of in vitro shockwave treatment on lymphatic endothelial cells." in: PLoS ONE, Vol. 9, Issue 12, pp. e114806, (2014) (PubMed).
: "
-
Molecular and cellular effects of in vitro shockwave treatment on lymphatic endothelial cells." in: PLoS ONE, Vol. 9, Issue 12, pp. e114806, (2014) (PubMed).
-
- FLT4 (Fms-Related Tyrosine Kinase 4 (FLT4))
-
别名
- VEGFR-3/FLT-4
-
背景
- Vascular endothelial growth factor receptor-3, FLT4, PCL, LMPH1A, VEGFR3, fms-related tyrosine kinase 4,VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk 1) and VEGFR-3 (FLT-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and kinase insert domains in their intracellular regions. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular and lymphatic endothelial cells and to the monocyte/macrophage lineage. These receptors play essential roles in vasculogenesis, hematopoiesis, angiogenesis and lymphangiogenesis. The VEGFR-3 cDNA encodes a 1298 amino acid (aa) residue precursor protein with a 24 aa residue signal peptide. Mature VEGFR-3 is composed of a 751 aa residue extracellular domain, a 22 aa residue transmembrane domain and a 482 aa residue cytoplasmic domain. Both VEGF-C and VEGF-D have been shown to bind and activate VEGF R3 (Flt-4). The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stage of development. It is important for lymphangiogenesis.
-
基因ID
- 2324
-
NCBI登录号
- NM_002020, NP_002011
-
UniProt
- P35916
-
途径
- RTK signaling, Signaling Events mediated by VEGFR1 and VEGFR2, VEGF Signaling
抗原
-